In the last trading session, 1.68 million Immunovant Inc (NASDAQ:IMVT) shares changed hands as the company’s beta touched 0.82. With the company’s per share price at $13.31 changed hands at -$1.08 or -7.51% during last session, the market valuation stood at $2.26B. IMVT’s last price was a discount, traded about -158.98% off its 52-week high of $34.47. The share price had its 52-week low at $13.59, which suggests the last value was -2.1% down since then. When we look at Immunovant Inc’s average trading volume, we note the 10-day average is 2.34 million shares, with the 3-month average coming to 1.68 million.
Analysts gave the Immunovant Inc (IMVT) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.29. If we narrow down to specifics, the data shows that 1 out of 20 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 6 recommended IMVT as a Hold, 13 felt it is a Buy and 0 rated the stock as Underweight.
Immunovant Inc (NASDAQ:IMVT) trade information
Instantly IMVT was in red as seen at the end of in last trading. With action -12.43%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -46.27%, with the 5-day performance at -12.43% in the red. However, in the 30-day time frame, Immunovant Inc (NASDAQ:IMVT) is -34.43% down. Looking at the short shares, we see there were 15.8 million shares sold at short interest cover period of 14.8 days.
The consensus price target for the stock as assigned by Wall Street analysts is 49, meaning bulls need an upside of 72.84% from its current market value. According to analyst projections, IMVT’s forecast low is 5 with 57 as the target high. To hit the forecast high, the stock’s price needs a -328.25% plunge from its current level, while the stock would need to tank 62.43% for it to hit the projected low.
The 2025 estimates are for Immunovant Inc earnings to decrease by -49.95%, but the outlook for the next 5-year period is at -21.29% per year.
IMVT Dividends
Immunovant Inc is expected to release its next quarterly earnings report on 2025-May-29.
Immunovant Inc (NASDAQ:IMVT)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 58.08% of Immunovant Inc shares while 49.64% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 118.41%. There are 49.64% institutions holding the Immunovant Inc stock share, with FMR LLC the top institutional holder. As of 2024-06-30, the company held 7.1765% of the shares, roughly 10.48 million IMVT shares worth $276.77 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 4.7138% or 6.51 million shares worth $171.86 million as of 2024-06-30.
Among Mutual Funds, the top two as of Feb 28, 2025 were Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . With 4.06 shares estimated at $54.01 million under it, the former controlled 2.39% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held about 1.22% of the shares, roughly 2.08 shares worth around $27.64 million.
